NOVAGO
DEAD

Serial Number

87771487

Owner

NovaGo Therapeutics AG

Attorney

Janice Housey

Filing Date

Jan 26, 2018

Add to watchlist:

No watchlists yet
View on USPTO

NOVAGO Trademark

Serial Number: 87771487 • Registration: 5877137

NOVAGO is a trademark filed by NovaGo Therapeutics AG on January 26, 2018. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently no longer active.

Owner Contact Info

NovaGo Therapeutics AG (3 trademarks)

Wagistrasse 27
Schlieren 8952 , CH

Entity Type: 99

Trademark Details

Filing Date

January 26, 2018

Registration Date

October 8, 2019

Published for Opposition

July 23, 2019

Cancellation Date

April 24, 2026

Goods & Services

Medical services; medical services in the field of immunity; provision of medical information; medical examinations, namely, assessments used for clinical research purposes; dispensing of pharmaceuticals; nutritional and dietary consultancy; consultancy and provision of information in the field of sanitary care; veterinary assistance in the nature of veterinary services, namely, assessments and procedures that leads to novel pharmaceutical products; beauty salon services; care services for animals, namely, for the regenerative treatment of veterinary trauma disorders; hygienic care; consultancy and provision of information relating to the operation, preparation, administration and dosage of pharmaceutical preparations

Chemical products, namely, for the regenerative treatment of disorders affecting human beings, including but not limited to, central nervous system, eye, skin and other disorders; chemical preparations for industrial purposes; chemical preparations for scientific use other than for medical or veterinary use; chemical preparations for photography; biological materials other than for medical or veterinary purposes, namely, biological monoclonal antibodies and formulations for human therapeutic use; biological preparations for use in industry and science; peptides for chemical products and foodstuffs in the nature of biological monoclonal antibodies and formulations for human therapeutic use; polypeptides; antibodies and proteins for scientific use

Pharmaceutical preparations, namely, for the regenerative treatment of disorders affecting human beings, including, but not limited to, central nervous system, eye, skin and other disorders; veterinary preparations, namely, for the regenerative treatment of disorders, including, but not limited to, central nervous system, eye, skin and other; preparations for immunotherapeutic purposes, namely, for the regenerative treatment of disorders affecting human beings, including, but not limited to, central nervous system, eye, skin and other disorders; products for the removal of tumors, namely preparations for neurodegenerative diseases, namely, but not limited to, traumatic brain injury, spinal cord injury, stroke; immunogens for medical use, namely, for the regenerative treatment of disorders affecting human beings, including, but not limited to, central nervous system, eye, skin and other disorders; vaccines, antibodies, epitopes for pharmaceutical use; peptides for pharmaceutical purposes; sanitary preparations for medical use for the regenerative treatment of disorders affecting human beings, including, but not limited to, central nervous system, eye, skin and other disorders; biological preparations for medical use for the treatment of neurological, ophthalmic, skin disorders; biocides; diagnostic products, namely, for the development of new therapeutic agents; towels for hygiene purposes, namely, sanitary towels; dietetic foods for medical use; dietetic beverages for medical use; protein antibodies for medical purposes, namely, for the regenerative treatment of disorders, including, but not limited to, central nervous system, eye, skin and other disorders

Monitoring of degenerative and traumatic disorders affecting human beings for quality control purposes; Research in the field of regenerative treatment of degenerative or traumatic human disorders research in the field of sanitary care; computer software design, computer programming; design and development of computer hardware; software development; consultancy and provision of information relating to quality control of pharmaceutical preparations, namely, preparations for regenerative treatment of human disorders; software maintenance

Filing History

CANCELLED SEC. 8 (6-YR)
Apr 24, 2026 C8..
TEAS CHANGE OF CORRESPONDENCE RECEIVED
May 19, 2025 TCCA
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
May 19, 2025 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
May 19, 2025 COAR
TEAS CHANGE OF CORRESPONDENCE RECEIVED
May 12, 2025 TCCA
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
May 12, 2025 ECDR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
May 12, 2025 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
May 12, 2025 REAP
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
May 12, 2025 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
May 12, 2025 COAR
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Oct 8, 2024 REM1
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Nov 10, 2023 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Nov 10, 2023 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Nov 10, 2023 REAP
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Jul 21, 2021 TCCA
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Jul 21, 2021 ECDR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jul 21, 2021 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jul 21, 2021 REAP
REGISTERED-PRINCIPAL REGISTER
Oct 8, 2019 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jul 23, 2019 NPUB
PUBLISHED FOR OPPOSITION
Jul 23, 2019 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jul 3, 2019 NONP
ELECTRONIC RECORD REVIEW COMPLETE
Jun 18, 2019 FIXD
ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED
Jun 14, 2019 ERRR
APPROVED FOR PUB - PRINCIPAL REGISTER
Jun 11, 2019 CNSA
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Jun 10, 2019 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Jun 10, 2019 COAR
TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 10, 2019 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 10, 2019 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jun 10, 2019 TROA
NOTIFICATION OF PRIORITY ACTION E-MAILED
Jan 10, 2019 GPRN
PRIORITY ACTION E-MAILED
Jan 10, 2019 GPRA
PRIORITY ACTION WRITTEN
Jan 10, 2019 CPRA
TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 12, 2018 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 12, 2018 CRFA
ASSIGNED TO LIE
Dec 12, 2018 ALIE
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Dec 6, 2018 ERSI
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Nov 29, 2018 GNS3
LETTER OF SUSPENSION E-MAILED
Nov 29, 2018 GNSL
SUSPENSION LETTER WRITTEN
Nov 29, 2018 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Nov 8, 2018 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Nov 8, 2018 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Nov 8, 2018 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
May 14, 2018 GNRN
NON-FINAL ACTION E-MAILED
May 14, 2018 GNRT
NON-FINAL ACTION WRITTEN
May 14, 2018 CNRT
ASSIGNED TO EXAMINER
May 9, 2018 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Feb 7, 2018 NWOS
NEW APPLICATION ENTERED
Jan 30, 2018 NWAP